Associations between second-hit alterations and disease type in CRISPR screening. (A) Proportion of samples harboring second-hit alterations for each gene according to sgRNA-targeted genes and disease type. Significantly recurrent genes (q < 1 × 10−10) are colored and marked with asterisks. (B) Type and position of second-hit alterations in Jak3, Jak1, Sh2b3, Flt3, Ptpn11, and Kit in the entire cohort (n = 104). (C) Proportion of samples harboring second-hit alterations involving FLT3, JAK/STAT, PI3K, and RAS pathway molecules in murine sgPax5-targeted B-cell malignancies (n = 26) and others (n = 78). Fisher exact test. (D) Proportion of samples harboring somatic alterations (mutations and structural variations) involving FLT3, JAK/STAT, PI3K, and RAS pathway molecules in human PAX5-altered subtypes of B-ALL/LBL (n = 85) and others (n = 738). Fisher exact test. aa, amino acids; FLT3, FMS-like tyrosine kinase 3; PI3K, phosphatidylinositol-3 kinase.

Associations between second-hit alterations and disease type in CRISPR screening. (A) Proportion of samples harboring second-hit alterations for each gene according to sgRNA-targeted genes and disease type. Significantly recurrent genes (q < 1 × 10−10) are colored and marked with asterisks. (B) Type and position of second-hit alterations in Jak3, Jak1, Sh2b3, Flt3, Ptpn11, and Kit in the entire cohort (n = 104). (C) Proportion of samples harboring second-hit alterations involving FLT3, JAK/STAT, PI3K, and RAS pathway molecules in murine sgPax5-targeted B-cell malignancies (n = 26) and others (n = 78). Fisher exact test. (D) Proportion of samples harboring somatic alterations (mutations and structural variations) involving FLT3, JAK/STAT, PI3K, and RAS pathway molecules in human PAX5-altered subtypes of B-ALL/LBL (n = 85) and others (n = 738). Fisher exact test. aa, amino acids; FLT3, FMS-like tyrosine kinase 3; PI3K, phosphatidylinositol-3 kinase.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal